Wave Life Sciences shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $15 to $22.
Portfolio Pulse from Benzinga Newsdesk
Wave Life Sciences shares surged after HC Wainwright reiterated a Buy rating and increased the price target from $15 to $22.
September 25, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wave Life Sciences shares are trading higher following HC Wainwright's decision to maintain a Buy rating and increase the price target from $15 to $22.
The increase in price target and maintained Buy rating by HC Wainwright is a positive signal to investors, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100